Established and privately held since 1994, Pharm-Olam is a leading mid-size CRO with multi-national presense in over 40 countries. Pharm-Olam delivers cost-effective, quick-to-market clinical services in emerging and traditional markets of research along with experience in a broad range of therapeutic areas and phases of development. Their CRAs average over 6 years of monitoring experience and the majority of their clinical staff in emerging markets are physicians or PhDs. Pharm-Olam data services integrate randomization into EDC systems, eliminating IVRS costs, with added benefit of full inventory control over supplies. Their multi-national pharma covigilance team provides 24/7 coverage from their safety units in USA and Europe to electronically collect, assess and report (S)AEs, SUSARs, and ADRs for secure reporting to sponsors, regulatory agencies, sites and ethics committees.